Recombinant alpha-galactosidase - Eleva
Alternative Names: Repleva aGAL; RPV-001Latest Information Update: 30 May 2024
At a glance
- Originator Eleva
- Class Enzymes; Recombinant proteins
- Mechanism of Action Alpha-galactosidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Fabry's disease
Most Recent Events
- 30 May 2024 RPV 001 is available for licensing as of 30 May 2024. https://elevabiologics.com/assets/ (Eleva pipeline, May 2024)
- 04 Jan 2024 Phase-I clinical trials in Fabry's disease (unspecified route) before January 2024
- 04 Jan 2024 Eleva completes a phase I trial in Fabry's disease (unspecified route)